IL237742A0 - Laquinimod and pridofidine for the treatment of neurodegenerative diseases - Google Patents
Laquinimod and pridofidine for the treatment of neurodegenerative diseasesInfo
- Publication number
- IL237742A0 IL237742A0 IL237742A IL23774215A IL237742A0 IL 237742 A0 IL237742 A0 IL 237742A0 IL 237742 A IL237742 A IL 237742A IL 23774215 A IL23774215 A IL 23774215A IL 237742 A0 IL237742 A0 IL 237742A0
- Authority
- IL
- Israel
- Prior art keywords
- pridopidine
- laquinimod
- neurodegenerative disorders
- treating neurodegenerative
- treating
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title 1
- 229960004577 laquinimod Drugs 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title 1
- 229950003764 pridopidine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Mechanical Engineering (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261706695P | 2012-09-27 | 2012-09-27 | |
| US201361879004P | 2013-09-17 | 2013-09-17 | |
| PCT/US2013/062482 WO2014052933A1 (en) | 2012-09-27 | 2013-09-27 | Laquinimod and pridopidine for treating neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL237742A0 true IL237742A0 (en) | 2015-05-31 |
Family
ID=50339469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL237742A IL237742A0 (en) | 2012-09-27 | 2015-03-15 | Laquinimod and pridofidine for the treatment of neurodegenerative diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (7) | US20150209346A1 (OSRAM) |
| EP (1) | EP2900330A4 (OSRAM) |
| CN (1) | CN104902958A (OSRAM) |
| AU (1) | AU2013323131A1 (OSRAM) |
| BR (1) | BR112015006623A2 (OSRAM) |
| CA (1) | CA2884781A1 (OSRAM) |
| EA (1) | EA201590655A8 (OSRAM) |
| HK (2) | HK1214553A1 (OSRAM) |
| IL (1) | IL237742A0 (OSRAM) |
| IN (1) | IN2015DN03219A (OSRAM) |
| MX (1) | MX2015003608A (OSRAM) |
| WO (1) | WO2014052933A1 (OSRAM) |
| ZA (1) | ZA201502600B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| PT2146961E (pt) * | 2007-04-12 | 2014-04-30 | Ivax Int Gmbh | Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US9006445B2 (en) | 2011-09-07 | 2015-04-14 | IVAX International GmbH | Polymorphic form of pridopidine hydrochloride |
| US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| ES2879631T3 (es) | 2013-06-21 | 2021-11-22 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento de la enfermedad de Huntington |
| KR20160110395A (ko) * | 2013-12-20 | 2016-09-21 | 테바 파마슈티컬 인더스트리즈 리미티드 | 헌팅턴병 진행을 지연시키기 위한 라퀴니모드의 용도 |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3193870A4 (en) * | 2014-09-16 | 2018-04-25 | Teva Pharmaceutical Industries Ltd. | Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| PL3261721T3 (pl) * | 2015-02-25 | 2022-12-27 | Prilenia Neurotherapeutics Ltd. | Stososowanie pridopidyny w celu poprawy pamięci |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| US20170020854A1 (en) * | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| PT3504187T (pt) | 2016-08-24 | 2025-05-09 | Prilenia Neurotherapeutics Ltd | Utilização da pridopidina no tratamento do declínio funcional |
| US11253594B2 (en) | 2017-07-07 | 2022-02-22 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Drug combinations for protecting against neuronal cell death |
| ES2938546T3 (es) * | 2017-08-14 | 2023-04-12 | Prilenia Neurotherapeutics Ltd | Método de tratamiento de la esclerosis lateral amiotrófica con pridopidina |
| WO2020188558A1 (en) * | 2019-03-15 | 2020-09-24 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| BR112021024744A2 (pt) * | 2019-06-12 | 2022-03-22 | Prilenia Neurotherapeutics Ltd | Método para melhorar, manter ou reduzir o comprometimento da capacidade funcional e função motora de um paciente humano com doença de huntington |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2528040T3 (es) * | 2007-06-18 | 2015-02-03 | A.Carlsson Research Ab | Uso de estabilizadores de dopamina |
| BRPI0920927A2 (pt) * | 2008-11-13 | 2019-09-24 | Link Medicine Corp | derivados de azaquinolinona e usos dos mesmos |
| EP2467372B1 (en) * | 2009-08-10 | 2016-05-18 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| US20120142730A1 (en) * | 2010-12-07 | 2012-06-07 | Nora Tarcic | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
-
2013
- 2013-09-27 CA CA2884781A patent/CA2884781A1/en active Pending
- 2013-09-27 US US14/426,327 patent/US20150209346A1/en not_active Abandoned
- 2013-09-27 IN IN3219DEN2015 patent/IN2015DN03219A/en unknown
- 2013-09-27 BR BR112015006623A patent/BR112015006623A2/pt active Search and Examination
- 2013-09-27 EP EP13840841.4A patent/EP2900330A4/en not_active Withdrawn
- 2013-09-27 HK HK16102362.8A patent/HK1214553A1/zh unknown
- 2013-09-27 CN CN201380050913.8A patent/CN104902958A/zh active Pending
- 2013-09-27 AU AU2013323131A patent/AU2013323131A1/en not_active Abandoned
- 2013-09-27 MX MX2015003608A patent/MX2015003608A/es unknown
- 2013-09-27 WO PCT/US2013/062482 patent/WO2014052933A1/en not_active Ceased
- 2013-09-27 HK HK15112317.4A patent/HK1211525A1/xx unknown
- 2013-09-27 US US14/040,586 patent/US20140088140A1/en not_active Abandoned
- 2013-09-27 EA EA201590655A patent/EA201590655A8/ru unknown
-
2015
- 2015-03-15 IL IL237742A patent/IL237742A0/en unknown
- 2015-04-17 ZA ZA2015/02600A patent/ZA201502600B/en unknown
-
2017
- 2017-07-20 US US15/655,580 patent/US20170319569A1/en not_active Abandoned
- 2017-11-02 US US15/801,703 patent/US20180133209A1/en not_active Abandoned
-
2018
- 2018-05-08 US US15/974,112 patent/US20180250285A1/en not_active Abandoned
- 2018-08-30 US US16/117,604 patent/US20180369228A1/en not_active Abandoned
- 2018-12-18 US US16/223,993 patent/US20190117639A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180369228A1 (en) | 2018-12-27 |
| WO2014052933A1 (en) | 2014-04-03 |
| US20180133209A1 (en) | 2018-05-17 |
| MX2015003608A (es) | 2015-06-05 |
| HK1214553A1 (zh) | 2016-07-29 |
| CA2884781A1 (en) | 2014-04-03 |
| CN104902958A (zh) | 2015-09-09 |
| AU2013323131A1 (en) | 2015-05-07 |
| EP2900330A4 (en) | 2016-05-25 |
| HK1211525A1 (en) | 2016-05-27 |
| US20150209346A1 (en) | 2015-07-30 |
| IN2015DN03219A (OSRAM) | 2015-10-02 |
| ZA201502600B (en) | 2016-06-29 |
| BR112015006623A2 (pt) | 2017-07-04 |
| EP2900330A1 (en) | 2015-08-05 |
| US20170319569A1 (en) | 2017-11-09 |
| US20190117639A1 (en) | 2019-04-25 |
| US20180250285A1 (en) | 2018-09-06 |
| EA201590655A8 (ru) | 2016-07-29 |
| US20140088140A1 (en) | 2014-03-27 |
| EA201590655A1 (ru) | 2015-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL237742A0 (en) | Laquinimod and pridofidine for the treatment of neurodegenerative diseases | |
| IL267066B (en) | Activin-actrii antagonists and their use for the treatment of bone and other disorders | |
| IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
| SI2830662T1 (sl) | Postopki zdravljenja motenj izgube las | |
| IL238416A0 (en) | Preparations and methods for the treatment of diseases caused by protein pathology | |
| ZA201404676B (en) | Compositions and methods for treating metabolic disorders | |
| EP2852349A4 (en) | PROCESS PLANNING SYSTEM | |
| DK3292875T3 (en) | Compositions and methods for treating diseases | |
| IL233140A0 (en) | Device and methods for treating nervous disorders | |
| EP2872146A4 (en) | TETRACYCLIN COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES | |
| GB201219873D0 (en) | Diverticulitis treatment | |
| TWI559917B (en) | Methods and compositions for treating neurodegenerative diseases | |
| IL238223A0 (en) | Methods and materials for the treatment of multiple sclerosis and diseases related to it | |
| IL233141B (en) | A pharmaceutical preparation for the treatment of hearing and balance disorders | |
| EP2847158A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS AND NEURODEGENERATIVE DISORDERS | |
| PL2861242T3 (pl) | Zaburzenia związane z glutenem | |
| IL246286A0 (en) | A medical preparation for the prevention and treatment of advanced myopia. | |
| ZA201504065B (en) | Therapeutic agent for keratoconjunctive disorders | |
| EP2919856A4 (en) | METHOD AND COMPOSITION FOR THE TREATMENT OF GASTRO-SOPHAGEAL DISORDERS | |
| IL238363A0 (en) | Methods for treating eye diseases | |
| AU2012904982A0 (en) | Device for treating respiratory disorders |